LEGN NASDAQ
Legend Biotech Corporation
1W: +13.4%
1M: +15.8%
3M: +14.4%
YTD: +0.2%
1Y: -32.3%
3Y: -67.6%
5Y: -60.5%
$21.56
+1.17 (+5.74%)
Weekly Expected Move ±7.4%
$16
$18
$19
$21
$22
Credit Risk of going bust: higher than 58% of companies Debt: 6.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.26 (down 99%), Legend Biotech Corporation would be worth roughly what it owes.
Total debt $278.2M against a stock market value of $3.99B.
Distance to default 4.36 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $168.2M (short-term plus half of long-term), stock volatility 71.9%; Altman Z'' 1.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.26 (down 99%), Legend Biotech Corporation would be worth roughly what it owes.
Total debt $278.2M against a stock market value of $3.99B.
Distance to default 4.36 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $168.2M (short-term plus half of long-term), stock volatility 71.9%; Altman Z'' 1.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $54.69 According to Brokerages
Legend Biotech (NASDAQ:LEGN) Director Corazon (Corsee) Sanders Sells 27,370 Shares of Company Stock
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to Analysts
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
10 mid-cap U.S. healthcare stocks with the weakest momentum grades
Legend Biotech appoints Ingrid Zhang as CEO
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.
SA Asks: What are the most promising oncology companies right now?
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
Here are the major earnings before the open Tuesday
Arrowstreet Capital Limited Partnership Acquires 315,176 Shares of Legend Biotech Corporation Sponsored ADR $LEGN
Legend Biotech (NASDAQ:LEGN) Shares Gap Down After Analyst Downgrade
Q2 EPS Estimates for Legend Biotech Boosted by HC Wainwright
2 Biotech Stocks Worth Buying Before Their Potential Buyouts
Legend Biotech Corporation (LEGN) Price Target Raised to $49 on LB5006 Clinical Progress
3 AI Infrastructure Stocks With Earnings Growth And Balance Sheet Checks - simplywall.st
Legend Biotech Corporation Stock 12‑Month Price Target Raised to $57.53, Implies 106% Upside - TradingView
Legend Biotech (LEGN) Stock Could Be 51.2% Undervalued After Equity Raise And LB2501 Data - simplywall.st
Legend Biotech (LEGN) Stock Could Be 51.2% Undervalued After Equity Raise And LB2501 Data - simplywall.st
$LEGN stock is down 15% today. Here's what we see in our data. - Quiver Quantitative
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Interim US-Iran Deal Lifts Risk Sentiment
Why Is Legend Biotech Stock Falling Thursday? - Benzinga
Why Is Legend Biotech Stock Falling Thursday?
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Legend Biotech (LEGN) Stock Could Be 51.2% Undervalued After Equity Raise And LB2501 Data - Sahm
Legend Biotech shares slide post-pricing of $226M public offering at $29.35 per unit
symbol__ Stock Quote Price and Forecast - CNN
Legend Biotech Announces Pricing of $226 Million Public Offering of ADSs - Quiver Quantitative
Legend Biotech sets $29.35 share price for $226M offering - Stock Titan
Legend Biotech Corporation Announces Pricing of Public Offering
Legend Biotech Corporation Announces Pricing of Public Offering
Legend Biotech stock falls on $225M share offering plan By Investing.com - Investing.com Nigeria
Legend Biotech stock falls on $225M share offering plan - Investing.com
Legend Biotech Corporation Announces Proposed Public Offering
Legend Biotech seeks $225M in stock sale as markets stay open - Stock Titan
Legend Biotech Unveils Strong First-in-Human Data for In Vivo CAR-T LB2501 at EHA 2026 - The Globe and Mail
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Legend Biotech Stock (LEGN) Opinions on In Vivo CAR-T Results - Quiver Quantitative
Why (LEGN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Legend Biotech (LEGN) Is Up 26.2% After Early In Vivo CAR-T Success in B-Cell Lymphoma
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results
12 Health Care Stocks Moving In Tuesday's Intraday Session
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture
Legend Biotech (LEGN) Presents Promising CAR-T Data at EHA 2026 - GuruFocus
$LEGN stock is up 26% today. Here's what we see in our data. - Quiver Quantitative
Legend's Cancer-Fighter Notches Elusive 100% Success Rate; What's Next?
Legend Biotech (NASDAQ: LEGN) shows 100% ORR for LB2501 in early NHL trial - Stock Titan
Early lymphoma trial: one-time CAR-T saw all higher-dose patients respond - Stock Titan
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
Legend Biotech (LEGN) Soars 42% on Promising Cancer Therapy Results - Yahoo Finance
$LEGN stock is up 26% today. Here's what we see in our data. - Quiver Quantitative
Legend Biotech CARVYKTI Data And Adoption Trends Meet Depressed Share Price
Legend Biotech CARVYKTI Data And Adoption Trends Meet Depressed Share Price - Yahoo Finance
Legend Biotech (LEGN) Reveals Promising CAR-T Therapy Data at AS - GuruFocus
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
Legend Biotech Corporation (LEGN) Stock Analysis: A Lucrative 103.96% Upside in the Biotech Space - DirectorsTalk Interviews
Legend Biotech Conference Spotlights CARVYKTI’s Curative Potential, Earlier Use
Legend Biotech (LEGN) Nears Adjusted Profitability This Year Amid Continued CARVYKTI Growth
Legend Biotech (LEGN) Nears Adjusted Profitability This Year Amid Continued CARVYKTI Growth - Yahoo Finance
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
Legend Biotech Announces Presentations at ASCO 2026
Legend Biotech Announces Presentations at ASCO 2026
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals
A China Tech Fund Opens a Biotech Position — Here's What That Actually Signals
Legend Biotech (LEGN) Valuation After Strong Q1 2026 CARVYKTI Growth And Narrowing Losses
Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Legend Biotech (LEGN) Valuation After Strong Q1 2026 CARVYKTI Growth And Narrowing Losses - Yahoo Finance
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says
Legend Biotech (LEGN) Trims Losses, Shares Climb Double-Digits
Legend Biotech (LEGN) Q1 2026 Earnings Transcript
Legend Biotech (LEGN) Q1 2026 Earnings Transcript
Legend Biotech Corp (LEGN) Q1 2026 Earnings Call Highlights: Strong CARVYKTI Sales and ...
Legend Biotech Q1 Earnings Call Highlights
Earnings Scheduled For May 12, 2026
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
Legend Biotech (LEGN) Trims Losses, Shares Climb Double-Digits - Yahoo Finance
LEGEND BIOTECH ($LEGN) Releases Q1 2026 Earnings - Quiver Quantitative
Legend Biotech Q1 2026 Earnings Preview
Is Legend Biotech (LEGN) Pricing Reflect Recent Share Rebound Or Longer Term Setbacks
Is Legend Biotech’s Expanded Scientific Board Quietly Redefining Its Long-Term CAR-T Strategy (LEGN)?
Is Legend Biotech (LEGN) Pricing Reflect Recent Share Rebound Or Longer Term Setbacks - Yahoo Finance
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last?
Legend Biotech (LEGN) Moves 18.4% Higher: Will This Strength Last? - Yahoo Finance
LEGN stock clocks best day in three years — what’s driving the rally? - MSN
Why Legend Biotech Stock Crushed the Market on Monday
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday
Legend Biotech (LEGN) Gets Bullish Ratings, PT Hike, Soars 18% - Yahoo Finance
$LEGN stock is up 9% today. Here's what we see in our data. - Quiver Quantitative
Is Legend Biotech (LEGN) One of the Overlooked Growth Stocks to Buy Now? - Yahoo Finance
Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright
Q2 EPS Estimates for Legend Biotech Reduced by HC Wainwright